Ann: Dimerix Receives Initial Upfront Payment from Advanz Pharma, page-102

There is no 'standard' pattern in the pathway to drug commercialisation.

The answer to your question is to be found in comparing DXB and NEU in their pathway milestones. You will see that NEU's licensing agreement and upfront payment of $10M occurred 1 year before the Phase 3 study for Retts commenced and 3 years before the results of the Phase 3 were announced in Dec 2021. The results were positive and the NEU share price doubled immediately and continued to rise in anticipation of further positive outcomes and then had its really big surge in Mar 2023 following FDA approval of the drug for Retts.

The comparison point you want is NOT the date of the licensing agreement and upfront payment but instead the date of First Phase 3 results I.e. Dec 2021 for Neu and Mar 2024 for DXB.